For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Difference in Hematologic Lab Abnormalities with JEVTANA 20 mg/m2 vs 25 mg/m2

Hematologic Lab Abnormalities in the PROSELICA Trial1

Grade 1-4
Grade 3-4
JEVTANA
20 mg/m2 +
prednisone
n=577
JEVTANA
25 mg/m2 +
prednisone
n=590
Absolute Difference JEVTANA
20 mg/m2 +
prednisone
n=577
JEVTANA
25 mg/m2 +
prednisone
n=590
Absolute Difference
Laboratory Abnormality Grade 1–4 Grade 3–4
Neutropenia 67% 89% -22% 42% 73% -31%
Anemia 99.8% 99.7% +0.1% 10% 14% -4%
Leukopenia 80% 95% -15% 29% 60% -31%
Thrombocytopenia 35% 43% -8% 3% 4% -1%

Protocol avoided prophylactic use of G-CSF during cycle 1.2
Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features:1

  • Older patients
  • Poor performance status
  • Previous episodes of febrile neutropenia
  • Extensive prior radiation ports
  • Poor nutritional status
  • Other serious comorbidities

Hematologic Lab Abnormalities in the TROPIC Trial1

In TROPIC, the most common (≥5%) grade 1-4 hematologic laboratory abnormalities for JEVTANA 25 mg/m2 + prednisone vs mitoxantrone were anemia (98% vs 82%), leukopenia (96% vs 93%), neutropenia (94% vs 87%), thrombocytopenia (48% vs 43%), and febrile neutropenia (7% vs 1%). The most common (≥5%) grade 3-4 hematologic laboratory abnormalities for JEVTANA 25 mg/m2 + prednisone vs mitoxantrone were neutropenia (82% vs 58%), leukopenia (69% vs 42%), anemia (11% vs 5%), and febrile neutropenia (7% vs 1%).

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel